key: cord-0820340-2wledlvt authors: Fisher, Christine R.; Medie, Felix Mba; Luu, Rebeccah J.; Gaibler, Robert; Miller, Caitlin R.; Mulhern, Thomas J.; Vijayakumar, Vidhya; Marr, Elizabeth; Alladina, Jehan; Medoff, Benjamin; Borenstein, Jeffrey T.; Gard, Ashley L. title: SARS-CoV-2 Viral Replication in a High Throughput Human Primary Epithelial Airway Organ Model date: 2021-06-16 journal: bioRxiv DOI: 10.1101/2021.06.15.448611 sha: 8238a84c7b6e0003dd156b212a9a47e6d1299b6b doc_id: 820340 cord_uid: 2wledlvt COVID-19 emerged as a worldwide pandemic early in 2020, and at this writing has caused over 170 million cases and 3.7 million deaths worldwide, and almost 600,000 deaths in the United States. The rapid development of several safe and highly efficacious vaccines stands as one of the most extraordinary achievements in modern medicine, but the identification and administration of efficacious therapeutics to treat patients suffering from COVID-19 has been far less successful. A major factor limiting progress in the development of effective treatments has been a lack of suitable preclinical models for the disease, currently reliant upon various animal models and in vitro culture of immortalized cell lines. Here we report the first successful demonstration of SARS-CoV-2 infection and viral replication in a human primary cell-based organ-on-chip, leveraging a recently developed tissue culture platform known as PREDICT96. This successful demonstration of SARS-CoV-2 infection in human primary airway epithelial cells derived from a living donor represents a powerful new pathway for disease modeling and an avenue for screening therapeutic candidates in a high throughput platform. COVID-19 emerged as a worldwide pandemic early in 2020 1 , and has since caused almost 600,000 deaths in the United States and nearly 4 million deaths world-wide 2 . The emergence of multiple safe and efficacious vaccines 3 has begun to turn the tide of infection and death in regions where the vaccine is widely available. The successful development of these vaccines in a matter of months represents an extraordinary achievement. However, the identification of effective treatments for COVID-19, either from re-purposed drugs or new therapeutic candidates, has lagged severely. A significant factor limiting progress is the absence of preclinical models that are predictive of human disease. Significant progress in the generation of animal models for COVID-19 research has recently been reported 4, 5 , but the availability and applicability of these models for wide use in pharmaceutical development remains a challenge. Preclinical cell culture models based on immortalized cell lines such as Vero E6 and A549 have also been reported 6, 7 , but lack key aspects of the host biology such as ciliary differentiation and mucociliary clearance believed to be critical in understanding pathogenesis and predicting therapeutic efficacy. Human primary airway epithelial cell culture at an air-liquid interface (ALI) represents a powerful platform technology for respiratory research 8 , with applications ranging from chronic pulmonary conditions to acute respiratory infections and toxic exposures to the lung. Recently, a Transwell™-based assay comprising human primary airway epithelial cell culture has also been used to investigate SARS-CoV-2 infection 9 . However, such membrane insert-based systems are quite limited in several key aspects, such as difficulties in high resolution imaging, large media volume, and the absence of dynamic media circulation and real-time sensing, relative to the organ-on-chip platform presented here. In response to these challenges, the field of organs-on-chips has turned intense attention toward modeling of respiratory pathogens such as influenza and SARS-CoV-2, and a number of groups have reported results relevant to the effort to establish therapeutic screening tools for these diseases [10] [11] [12] [13] . These platforms utilize human primary alveolar or airway epithelial cells in microfluidic organ models designed to closely mimic not only the relevant cell biology but other key aspects of the in vivo microenvironment. To date, these studies have been limited to analysis of SARS-CoV-2 pseudoviruses due to significant challenges in both accessing and executing organ-on-chip experiments in BioSafety Level 3 (BSL-3) facilities. While pseudoviruses represent a potentially useful and convenient model for the study of viral entry, several key studies of neutralizing antibodies against SARS-CoV-2 14 and in particularly highly transmissible variants 15 indicate that they do not always accurately reflect neutralization of the live virus. Furthermore, in lacking the viral life cycle of wildtype viruses, pseudoviruses are less suitable screening tools for compounds that may target stages other than viral entry. This and other related considerations spurred our efforts to investigate viral infection kinetics of the live SARS-CoV-2 virus in the PREDICT96-ALI platform in a BSL-3 laboratory environment. Here we report the first demonstration of SARS-CoV-2 infection and viral replication in a human primary cell-based airway-on-a-chip organ model. We utilized the PREDICT96- This report is based on an initial set of experiments with a single donor population of human primary airway epithelial cells. Further studies with additional donor cells are underway, but this first successful demonstration of SARS-CoV-2 infection in a human primary organ-on-chip model represents an exciting milestone and opportunity for modeling pandemic respiratory infections. The streamlined applicability of this platform for BSL-3 operation, combined with its inherent high throughput nature, integrated perfusion, in situ imaging, and sensing capabilities 16, 17 render PREDICT96 a powerful tool for modeling respiratory infections, and an avenue for screening therapeutic candidates for treatment of these severe diseases in a rapid and efficient manner. The PREDICT96 organ-on-chip platform consists of a microfluidic culture plate with 96 individual devices and a perfusion system driven by 192 microfluidic pumps integrated into the plate lid 17 . As described in our previous work 13, [16] [17] [18] , in order to establish recirculating flow in the microchannels, we incorporate a self-priming micropump array into the lid that serves as the fluidic interface with the culture plate via stainless steel tubes. The PREDICT96 pumping system has 192 individual pneumatically-actuated micropumps embedded in the plate lid: two per culture device, one for the chamber above the membrane and one for below. However, since the upper chamber is at air-liquid interface (ALI), only the 96 pumps serving the microchannel are in use during experiments. Actuation of the pumps transfers media between the wells linked by the bottom microfluidic channel and establishes a hydrostatic pressure differential, inducing flow through each microchannel. Human small airway epithelial cells were isolated from living donors by research bronchoscopy at Massachusetts General Hospital (MGH), Boston, MA. Bronchoscopy brushings were collected into collection media (RMPI (ThermoFisher) + 2% human serum albumin (ThermoFisher) + 5 µM ROCKi (Tocris)) and transported on ice to Draper (Cambridge, MA) 19 . All research involving human subjects was approved by the MGH and Partners Healthcare System Institutional Review Board, and adhered to all applicable institutional and sponsor ethical guidelines, including but not limited to anonymization of donors for personal identity. All methods were in adherence with applicable safety and laboratory practice guidelines. After isolation and transport to Draper, human small airway epithelial cells were spun down at 200 x g for 5 min, re-suspended in SAGM + 4i media, and transferred to a well plate coated with 804G media (804G media production described previously 19, 20 ) . Donor cells reported in this manuscript were derived from donor DH01: 28 years, female, Asian (non-Hispanic). Cells were cultured in SAGM + 4i media 13 , and passaged using Accutase (Sigma). After 4 passages, cells were cryopreserved in Cryostor 10 (STEMCELL Technologies). PREDICT96-ALI plates were prepared as previously described 13 . DH01 cells were thawed and plated at 15,000 cells per device in a 3 µL volume directly onto the membrane. Cell/tissue growth in submerged and then ALI conditions was conducted as previously reported in a custom-ALI media 13 . Tissues were matured over the course of 4 weeks in ALI culture prior to viral infection experiments. To remove accumulated mucus from the apical surface of the maturing tissue, 100 µL of 1x Hank's Balanced Salt Solution (HBSS, Sigma) was added to the apical surface of each tissue and incubated on the tissues for 1 h at 37 ⁰C with rocking, subsequently followed by an additional 5 min wash with 100 µL of 1x HBSS at room temperature every 7 days (d). Downstream processing of tissues following viral inoculation included tissue apical washes, basal media collection, harvest of tissue for RNA extraction, and fixation for immunofluorescence imaging. Immunofluorescence staining was conducted as previously reported 13 . Primary antibodies were used to stain basal cells (CK5, Thermo Fisher), goblet cells (Muc5A, Thermo Fisher), ciliated cells (acetylated-tubulin, Abcam) and SARS-CoV-2 (Spike and Nucleocapsid proteins, GeneTex). The SARS-CoV-2 Spike and Nucleocapsid protein antibodies were combined when added to the PREDICT96-ALI airway tissues during primary antibody incubation steps. Secondary antibodies used were Alexa Fluor 488 goat anti-mouse IgG (Thermo Fisher) and Alexa Fluor 555 goat anti-rabbit IgG (Thermo Fisher). Tissues were incubated with counter-stains Hoechst 33342 dsDNA nuclear stain (ThermoFisher) and Phalloidin-iFluor 647 reagent (Abcam). Immunofluorescent labeled PREDICT96-ALI tissues were imaged in situ within the PREDICT96-ALI plate by way of the optical qualities of the PREDICT96-ALI platform and using a Zeiss LSM700 laser scanning confocal microscope and Zen Black software (Zeiss). Tile scans and z-stacks of the tissues at 40x and 10x magnification were acquired. 10x tile scans of the middle of each PREDICT96-ALI tissue device were captured on a Zeiss LSM700 laser scanning confocal microscope with Zen Black software (Zeiss). The MFI of the signal from the red channel, or the Nucleocapsid and Spike protein expression, of these regions was measured via ImageJ Fiji. The average signal from the secondary only controls were subtracted to remove the background signal, and the average MFI from each infection condition was calculated. After 4 weeks of ALI culture of DH01 human primary airway epithelial cells, basal media samples were collected for quantification of soluble CCSP via a premade Magnetic Luminex Performance Assay kit (Uteroglobin/SCGB1A1, R&D Systems). Culture media was collected from the bottom chamber of each tissue device and immediately frozen at -20°C until use. Undiluted media samples were processed according to the manufacturer's protocol and analyzed via a Luminex FLEXMAP 3D. The data collected were used to generate standard curves for each analyte using a five parameter logistic (5-PL) curve-fit to determine the concentration of CCSP in the sample. Concentration of CCSP concentration was measured for each individual PREDICT96-ALI microtissue device, and devices derived from the same experimental conditions were averaged together and reported as mean ± standard deviation (N=6 devices). SARS-CoV-2 strain USA-WA1/2020, passage 4 virus was obtained from Joseph Brewoo and Sam R. Telford III (New England Regional Biosafety Laboratory, Global Heath & Infectious Disease, Tufts University). All of the work with SARS-CoV-2 was performed at BSL-3. Inoculation of PREDICT96-ALI airway tissues with SARS-CoV-2 (and mock control) was performed similarly to coronavirus infections described previously 13 Viral RNA was extracted from HBSS wash samples and tissue RNA was extracted from microtissue devices as previously described 13 Wash samples collected from inoculated PREDICT96-ALI plates were titered via plaque assay as previously reported 22 of plaques / (dilution x total inoculum volume (mL)). Data are presented as mean ± standard deviation or standard error of the mean (indicated in figure legends) and were analyzed using Graphpad Prism version 9.0.0 for Windows (GraphPad Software). Statistical significance was determined using one-or two-way analysis of variance (ANOVA) with Tukey's post hoc test for multiple comparisons, where appropriate. A p-value lower than 0.05 was considered statistically significant. (basal cells) ( Figure 1C) . Moreover, the airway tissues displayed robust RNase P transcript quantities and had no measurable levels of SARS-CoV-2 N1 and N2 viral proteins detected prior to inoculation with wild-type SARS-CoV-2 ( Figure 1D) . Altogether, the PREDICT96-ALI tissues were in a mature, differentiated state and negative for SARS-CoV-2 prior to initiation of SARS-CoV-2 infection studies at 4 weeks of ALI. Next, we examined the effect of inoculation of mature PREDICT96-ALI airway tissue with SARS-CoV-2 infection in PREDICT96-ALI airway tissues was additionally characterized by immunofluorescence microscopy. Figure 3A shows All authors declare no conflict of interests. (C) Macroscopic images of 6-well plaque assay wells corresponding to data displayed in panel B. Coronavirus Infections-More Than Just the Common Cold Safety and Efficacy of the BNT162b2 mRNA Covid-19 Animal models for COVID-19 Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV